Küker W, Nägele T, Thiel E, Weller M, Herrlinger U
Department of Neuroradiology, Medical School, University of Tübingen, Berlin, Germany.
Neurology. 2005 Oct 11;65(7):1129-31. doi: 10.1212/01.wnl.0000178894.51436.54.
The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL). Four of 68 patients with persisting contrast-enhancing lesions after primary therapy did not receive further therapy, and none showed tumor progression after up to 54 months. Because contrast enhancement may not necessarily indicate residual, biologically active lymphoma, the authors propose a modification of the Macdonald response criteria.
作者研究了麦克唐纳反应标准对原发性中枢神经系统淋巴瘤（PCNSL）患者的适用性。68例在初始治疗后仍有持续强化病灶的患者中，有4例未接受进一步治疗，且在长达54个月的时间里均未出现肿瘤进展。由于强化不一定表明存在残留的、具有生物学活性的淋巴瘤，作者提议对麦克唐纳反应标准进行修订。
